FGFR2 and neoplasm: Our results may inform clinical decisions regarding personalized therapeutic modulation of EGFR/ERK and Notch signalling pathways in this high‐risk population and reveal the potential utility of ADAM17 inhibition in treating patients with EC and more broadly patients with other FGFR2‐dependent tumours.